<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04012541</url>
  </required_header>
  <id_info>
    <org_study_id>AMI oral intervention</org_study_id>
    <nct_id>NCT04012541</nct_id>
  </id_info>
  <brief_title>Comprehensive Oral Intervention in Patients With AMI</brief_title>
  <official_title>A Randomized Control Trial of Comprehensive Oral Intervention in Patients With Acute Myocardial Infarction: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Research Foundation of Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators performed a randomized controlled trial with investigator-masked design
      enrolling subjects with acute myocardial infarction.

      The purpose of this study is to find a treatment strategy to reduce the risk of recurrence of
      myocardial infarction through oral hygiene improvement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects were divided into a treatment group and a control group. Both sides receive basic
      periodontal examinations, but the treatment group receives active dental procedure such as
      scaling and root planing. Both groups also receive post-myocardial infarction management.

      As part of a pilot study, this study used the primary outcome measure for changes in
      surrogate markers rather than clinical outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study is randomized controlled trial. Patients who agreed to the study were randomly assigned to the intervention group and control group at a 1: 1 ratio.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>Participating patients and dentists are not able to blind information about random allocation. However, in order to reduce the bias, the cardiologist who treats the patient and prescribes the medicines performs an investigator-masked design that masks information about the treatment group.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>hsCRP</measure>
    <time_frame>at 3 months</time_frame>
    <description>hsCRP(high sensitivity C-reactive protein), mg/dL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>surrogate blood markers</measure>
    <time_frame>at 3 months</time_frame>
    <description>FBS &amp; Total cholesterol &amp; LDL-cholesterol &amp; HDL-cholesterol &amp; Triglyceride &amp; Apolipoprotein A &amp; Apolipoprotein B, mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient symptom</measure>
    <time_frame>at 3 months &amp; 12 months</time_frame>
    <description>NYHA functional class</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic &amp; diastolic blood pressure</measure>
    <time_frame>at 3 months &amp; 12 months</time_frame>
    <description>automated blood pressure, mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise performance</measure>
    <time_frame>at 3 months</time_frame>
    <description>Treadmill test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>at 12 months</time_frame>
    <description>number of cardiovascular death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>unscheduled coronary revascularization</measure>
    <time_frame>at 12 months</time_frame>
    <description>number of unscheduled coronary revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stroke</measure>
    <time_frame>at 12 months</time_frame>
    <description>number of stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HF admission</measure>
    <time_frame>at 12 months</time_frame>
    <description>number of HF admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>unstable angina</measure>
    <time_frame>at 12 months</time_frame>
    <description>number of unstable angina</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>recurrent MI</measure>
    <time_frame>at 12 months</time_frame>
    <description>number of recent MI</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <condition>Dental Diseases</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>post-myocardial infarction management
basic periodontal examinations
active dental procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>post-myocardial infarction management
basic periodontal examinations</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>active dental procedure</intervention_name>
    <description>scaling and root planing</description>
    <arm_group_label>treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>post-myocardial infarction management</intervention_name>
    <description>aspirin, clopidogrel, ticagrelor</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>treatment group</arm_group_label>
    <other_name>dual antiplatelet drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>basic periodontal examinations</intervention_name>
    <description>panorama radiograph : full mouth periapical radiograph</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults over 18

          -  Patients diagnosed with type 1 or 2 MI according to the Fourth Universal Definition of
             Myocardial Infarction (2018) criteria

          -  Patients with baseline hsCRP (high-sensitivity C-reactive protein) elevated above 1.0
             mg / dL

        Exclusion Criteria:

          1. clinical exclusion criteria

               -  Inability to provide informed consent

               -  Patients who are predicted to have low compliance

               -  Those whose life expectancy is less than 3 months due to cardiovascular disease
                  or other reasons

               -  Those who are considered to be too poor condition to perform dental treatment or
                  have a high risk of bleeding

               -  Those who need active dental treatment such as extraction

               -  Patients suspected of having active infection

               -  Those who are taking long-term systemic antibiotics or receiving
                  immunosuppressive treatment

          2. periodontal exclusion criteria

               -  Fully edentulous (Except for fixed implant restorations)

               -  If more than 15 teeth and implants do not exist

               -  If the last dental visit experience is less than 6 months

               -  If periodontal treatment is not possible by the researcher
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Si-Hyuck Kang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Si-Hyuck Kang, MD</last_name>
    <phone>82317877027</phone>
    <email>eandp303@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ji Yeon Yoon</last_name>
    <phone>82317873974</phone>
    <email>r1999@snubh.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Si-Hyuck Kang, MD</last_name>
      <phone>82317877027</phone>
      <email>eandp303@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ji Yeon Yoon</last_name>
      <phone>82317873974</phone>
      <email>r1999@snubh.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 14, 2019</study_first_submitted>
  <study_first_submitted_qc>July 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2019</study_first_posted>
  <last_update_submitted>July 8, 2019</last_update_submitted>
  <last_update_submitted_qc>July 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Si-Hyuck Kang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Stomatognathic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

